Delivery of insulin to the buccal mucosa utilizing the RapidMist™ system

Expert Opinion on Drug Delivery

Volumn 5, Issue 9, 2008, Pages 1047-1055

  Bernstein, Gerald ^a,b,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Generex Biotechnology ^*

^c Friedman Diabetes Institute   (United States)

Author keywords

Buccal mucosa; Diabetes mellitus; Insulin

Indexed keywords

FENTANYL; GLITAZONE DERIVATIVE; GLYCERYL TRINITRATE; HUMAN INSULIN; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; LOW MOLECULAR WEIGHT HEPARIN; METFORMIN; MORPHINE; NIFEDIPINE; RECOMBINANT HUMAN INSULIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT;

ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; DIABETES MELLITUS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; LUNG CANCER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; UNSPECIFIED SIDE EFFECT; ANIMAL; CHEEK; METABOLISM; MOUTH MUCOSA;

ANIMALS; CHEEK; DIABETES MELLITUS; DRUG DELIVERY SYSTEMS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MOUTH MUCOSA;

EID: 54049114336     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.5.9.1047     Document Type: Review

References (12)

1. The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 1993;329:977-86
2. Turner RC, Cull C, Holman R. UKPDS 17: a nine year update on type 2 diabetes. Ann Intern Med 1996;124(1 Pt 2):136-45
3. Zambanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin treated diabetes. Diabetes Res Clin Pract 1999;46:239-46
4. De Vries ME, Bodde HF, Verheof JC, Junginger HE. Developments in Drug Delivery. Crit Rev Ther Drug Carrier Syst 1991;8:271-303
5. Modi P, Mihic M, Lewin A. The evolving role of oral insulin in the treatment of diabetes using a novel RapidMist™ system. Diabetes Metab Res Rev 2002;18(Suppl 1)S38-42
6. Guevera-Aguirre J, Guevara-Aguirre M, Rosenbloom ABG. Oral Presentation Endocrine Sociery 90th Annual Meeting; June 2008
7. Guevara-Aguirre J, Guevara M, Saavedra J, et al. Beneficil effects of addition of oral spray insulin (Oralin) on insulin secretion and metabolic control in subjects with type 2 diabetes mellitus suboptimally controlled on oral agents. Diabetes Technol Ther 2004;6:1-8
8. Guevara-Aguirre J, Guevarra-Aguirre M, Saveedra J, et al. Comparison of oral insulin spray and subcutaneous regular insulin at meal time in type 1 diabetes. Diabetes Technol Ther 2007;9:372-7
9. Guevara-Aguirre J, Guevera-Aguirre M, Saveedra J, Bernstein G. 6 Month safety and efficacy of oral insulin administered at lunchtime in juvenile type 1 subjects receiving basal glargine insulin and pre-breakfast and pre-dinner S>C> regular insulin [abstract]. Endocrine Society 89th Annual Meeting; 2007
10. Guevara-Aguirre J, Guevara-Aguirre M, Saavedra J. A comparison of metabolic control of preprandial S.C. Regular insulin versus prandial split doses of an oral insulin (Generex Oral-lyn) in well controlled type 1 diabetes mellitus subjects maintained on twice daily NPH insulin. [abstract]. Endocrine Society 89th Annual Meeting; June 2007
11. Cernea S, Kidron M, Wohlgelernter J, et al. Comparison of pharmacokinetic and pharmacodynamic properties of single dose oral insulin spray and subcutaneous insulin injections in healthy subjects using the euglycemic clamp techniques. Clin Ther 2004;26:2084-91
12. Cernea S, Kidron M, Wohlgelernter J, et al. Diabetes Care 2003;28:1353-7